Arthneeti
Latest: Dishman Carbogen Amcis Ltd Q1 FY27 (Apr–Jun 2026) results →This page is Q1 FY26 (Apr–Jun 2025).All Q1 FY26 results →
DC

Dishman Carbogen Amcis Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Dishman Carbogen Amcis Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Price₹174
Market cap₹3.0K Cr
P/E164.8
Updated23 Aug 2026
Read3 min read

Dishman Carbogen Amcis Ltd Q1 FY26 key numbers

Revenue
Development pipeline at approximately 117 million Swiss francs as of June 30, 2025; commercial order book around 77 million Swiss francs (Q2 2025).

As stated in Dishman Carbogen Amcis Ltd's Q1 FY26 earnings call transcript · published 14 Jun 2026. Reported figures, not investment advice.

The short version

Development pipeline at approximately 117 million Swiss francs as of June 30, 2025; commercial order book around 77 million Swiss francs (Q2 2025).

From Dishman Carbogen Amcis Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Development pipeline at approximately 117 million Swiss francs as of June 30, 2025; commercial order book around 77 million Swiss francs (Q2 2025).
  • Full-year revenue and profitability expected to increase compared to the previous year; Q2 likely to pick up with integration efforts between Switzerland, India, and France facilities.
  • France facility expects revenue growth to reduce current EBITDA losses over the year.
  • HiPo facility in India (Bavla) is being evaluated for new projects; positive outlook for re-starting operations soon.

2 more points from Dishman Carbogen Amcis Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Dishman Carbogen Amcis Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Co-investment in new facility in Switzerland with a large Japanese customer focused on ADC products.
  • Japanese customer's investment: 15 million CHF initially; second round investment 25 million CHF, with Dishman contributing internal hours, not cash.
  • Full-year CAPEX guidance reduced to below initial 25 million Swiss francs estimate; Q1 CAPEX was around US$5.6 million (~4 million CHF).
  • Focus on expanding soft gel manufacturing in India (Bavla) targeting semi-regulated markets with growing commercial quantities.
  • Efforts ongoing to restart and generate revenues from the HiPo facility in Bavla, India.

2 more points from Dishman Carbogen Amcis Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Dishman Carbogen Amcis Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • As of June 30, 2025:
  • Development pipeline: Approximately 117 million Swiss francs.
  • Commercial order book: Roughly 77 million Swiss francs (for Carbogen Amcis).

2 more points from Dishman Carbogen Amcis Ltd's call on order book

Create a free account to keep reading this call

Dishman Carbogen Amcis Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹851 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Dishman Carbogen's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG LifeScience. (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharma. (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Labs. (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Dishman Carbogen Amcis Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Dishman Carbogen Amcis Ltd Q1 FY26 results?

Development pipeline at approximately 117 million Swiss francs as of June 30, 2025; commercial order book around 77 million Swiss francs (Q2 2025).

What is Dishman Carbogen Amcis Ltd share price analysis?

Dishman Carbogen Amcis Ltd currently shows a neutral. The stock trades at a P/E of 164.8 with a market cap of ₹2,989 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dishman Carbogen Amcis Ltd planning capital expenditure?

Co-investment in new facility in Switzerland with a large Japanese customer focused on ADC products.

Keep Dishman Carbogen Amcis Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.